Biomea Fusion, Inc.

Gilead Sciences, Inc.

Other

Thomas Butler

Choung U Kim

Aesop Cho

Matthew Welsch

Ravi Upasani

Sridhar Vempati

Brendan Kelly

Edward Painter

Jim Palmer

Oliver L Saunders

Lijun Zhang

Jay P Parrish

Jie Xu

James T Palmer

Nan-Horng Lin

Samuel E Metobo

Benjamin R Graetz

Andrew W Waltman

T Glen Butler

Thorsten A Kirschberg

Xiaodong Wang

Thu Phan

Ravindra B Upasani

Yongli Su

Siyi Jiang

Daniel Lu

Angelina Sau Man Wong

Heow Meng Tan

Hongyan He

Albert Stellar

David Sperandio

Solomon B Ungashe

Amna Trinity-Turjuman Adam

Neil Howard Squires

Taisei Kinoshita

Brian Law

Priyanka Somanath

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Inhibitors of menin-MLL interaction

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes mellitus.

Covalent inhibitors of menin-MLL interaction for diabetes mellitus

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Substituted pyridines as irreversible inhibitors of menin-MLL interaction

Irreversible inhibitors of menin-MLL interaction

Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (I) including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include compound (I), as well as methods of using compound (I), alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction

Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Pyrazine compounds as inhibitors of FLT3

Inhibitors of menin-mll interaction

Disclosed herein are heterocyclic compounds according to formula (I) having the structure that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-HLL interaction. Also disclosed are pharmaceutical compositions that include compounds according to formula (I). Methods of using the menin-HLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

A self leveling picture frame assembly for automatically leveling a picture includes a picture frame defining a viewing space to display a picture. An insert is insertable into the picture frame to retain the picture in the picture frame. A leveling chamber is integrated into the insert and the leveling chamber contains a leveling fluid. The total quantity of leveling fluid is substantially less than a volume of the leveling chamber thereby facilitating the leveling fluid to travel freely in the leveling chamber. Moreover, the leveling fluid collects in the lowest point of the leveling chamber when the picture frame is hung on a vertical support surface. In this way the leveling fluid can level the picture frame on the vertical support surface.

Self leveling picture frame assembly

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction; or a pharmaceutically acceptable salt thereof.

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL inter-action; or a pharmaceutically acceptable salt thereof.

Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I. 

Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs

A self-leveling picture frame apparatus for automatically leveling pictures hung on a wall includes a frame body having an upper portion, a lower portion, a left portion, and a right portion defining a frame aperture. A leveling liquid is coupled within a leveling cavity of the frame body. The leveling cavity is shaped to direct the leveling liquid towards a midline of either the upper portion, the lower portion, the left portion, or the right portion depending on which portion is lowest. A transparent front cover is coupled to the frame body. The front cover is coupled to a front face of the frame body within the frame aperture. A back cover is coupled to a back face of the frame body over the frame aperture.

Self-leveling picture frame apparatus

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

1'-substituted carba-nucleoside analogs for antiviral treatment

Growing community of inventors

Redwood City, CA, United States of America

Thomas Butler